Assisted Reproduction - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Assisted Reproduction

The Experts below are selected from a list of 26193 Experts worldwide ranked by ideXlab platform

Fernando Antoñanzas – 1st expert on this subject based on the ideXlab platform

  • Pharmaceutical Costs of Assisted Reproduction in Spain
    Clinical Drug Investigation, 2013
    Co-Authors: Maria-reyes Lorente, Juana Hernández, Fernando Antoñanzas

    Abstract:

    BackgroundAssisted Reproduction is one of the health services currently being considered for possible limitation or exclusion from the public health services portfolio in Spain. One of the main reasons claimed for this is the impact on the budget for pharmaceutical expenditure.ObjectiveThe objective of this study was to assess the significance of the pharmaceutical costs of Assisted Reproduction in Spain.MethodsThis study focused on medical practice in Spain, and is based on the opinions of experts in Assisted Reproduction and the results provided by professional societies’ publications. The reference year is 2012 and the setting was secondary care. We have included all existing pharmaceutical modalities for Assisted Reproduction, as well as the most common drug for each modality. We have considered the pharmaceutical cost per cycle for artificial insemination, in vitro fertilisation with or without intracytoplasmic sperm injection (IVF_ICSI), and cryotransfer and donated fresh oocytes reception.ResultsIn Spain, artificial insemination has a pharmaceutical cost per cycle of between €69.36 and €873.79. This amounts to an average cycle cost of €364.87 for partner’s sperm and €327.10 for donor sperm. The pharmaceutical cost of IVF_ICSI ranges between €278.16 and €1,902.66, giving an average cost per cycle of €1,139.65. In the case of cryotransfer and donated fresh oocytes reception, the pharmaceutical cost per cycle is between €22.61 and €58.73, yielding an average cost of €40.67. The budgetary impact of pharmaceutical expenditure for Assisted Reproduction in Spain for the year 2012 was estimated at €98.7 million.ConclusionIn Spain, the total pharmaceutical cost of Assisted Reproduction is substantial. According to our results, we can say that about 29 % of the total pharmaceutical expenditure for Assisted Reproduction techniques is funded by the National Health System and the rest represents 2.4 % of the total annual out-of-pocket family expenditure on drugs.

  • Pharmaceutical Costs of Assisted Reproduction in Spain
    Clinical Drug Investigation, 2013
    Co-Authors: Maria-reyes Lorente, Juana Hernández, Fernando Antoñanzas

    Abstract:

    Background
    Assisted Reproduction is one of the health services currently being considered for possible limitation or exclusion from the public health services portfolio in Spain. One of the main reasons claimed for this is the impact on the budget for pharmaceutical expenditure.

L P De Boer – 2nd expert on this subject based on the ideXlab platform

  • Assisted Reproduction treatment and epigenetic inheritance
    Human Reproduction Update, 2012
    Co-Authors: A P A Van Montfoort, L L P Hanssen, P De Sutter, Stephane Viville, Joep P M Geraedts, L P De Boer

    Abstract:

    BACKGROUND
    The subject of epigenetic risk of Assisted Reproduction treatment (ART), initiated by reports on an increase of children with the Beckwith–Wiedemann imprinting disorder, is very topical. Hence, there is a growing literature, including mouse studies.

Marcandre Sirard – 3rd expert on this subject based on the ideXlab platform

  • omics in Assisted Reproduction possibilities and pitfalls
    Molecular Human Reproduction, 2010
    Co-Authors: Emre Seli, Claude Robert, Marcandre Sirard

    Abstract:

    A key step in Assisted Reproduction is the assessment of oocyte and embryo developmental potential in order to determine the embryo(s) most likely to result in pregnancy. Currently used embryo assessment strategies are largely based on embryo morphology and cleavage rate. Although these systems have been successful in improving pregnancy rates and reducing multiple gestations, their precision is still insufficient. Therefore, development of an objective, accurate, fast and affordable test that can aid in the assessment of oocyte and embryo developmental potential is a significant aim of reproductive medicine. Recently, global assessment strategies involving genomic, tran- scriptomic, proteomic or metabolomic profiling of oocytes, granulosa or cumulus cells, embryos or culture media have been applied to Assisted Reproduction. These technologies are at different stages of development and present unique advantages as well as limitations.